All Stories

  1. Validation of pixel-wise parametric mapping of myocardial blood flow with 13NH3 PET in patients with hypertrophic cardiomyopathy
  2. An Investigation of the Molecular Mechanism of Double cMyBP-C Mutation in a Patient with End-Stage Hypertrophic Cardiomyopathy
  3. 2014 ESC Guidelines on Diagnosis and Management of Hypertrophic Cardiomyopathy
  4. Late gadolinium enhancement score (LGE-Score) for prediction of extensive late gadolinium enhancement in hypertrophic cardiomyopathy
  5. Clinical Phenotype and Outcome of Hypertrophic Cardiomyopathy Associated With Thin-Filament Gene Mutations
  6. Significance of Sarcomere Gene Mutations Analysis in the End-Stage Phase of Hypertrophic Cardiomyopathy
  7. Consensus recommendation on Fabry disease diagnosis in adult patients with left ventricular hypertrophy
  8. Coronary microvascular dysfunction is an early feature of cardiac involvement in patients with Anderson-Fabry disease
  9. Prognostic Value of N-Terminal Pro-Brain Natriuretic Peptide in Outpatients With Hypertrophic Cardiomyopathy
  10. Hypertrophic cardiomyopathy: The need for randomized trials
  11. Relationship of ECG findings to phenotypic expression in patients with hypertrophic cardiomyopathy: A cardiac magnetic resonance study
  12. Obesity and its Association to Phenotype and Clinical Course in Hypertrophic Cardiomyopathy
  13. Erratum to: Early Results of Sarcomeric Gene Screening from the Egyptian National BA-HCM Program
  14. Molecular Modeling of Disease Causing Mutations in Domain C1 of cMyBP-C
  15. Anderson-Fabry, the histrionic disease: from genetics to clinical management
  16. Early Results of Sarcomeric Gene Screening from the Egyptian National BA-HCM Program
  17. Report on the 2nd Florence International Symposium on Advances in Cardiomyopathies: 9th meeting of the European Myocardial and Pericardial Diseases WG of the ESC
  18. β Blockers for Prevention of Exercise-Induced Left Ventricular Outflow Tract Obstruction in Patients With Hypertrophic Cardiomyopathy
  19. Clinical and molecular classification of cardiomyopathies
  20. Pattern and degree of left ventricular remodeling following a tailored surgical approach for hypertrophic obstructive cardiomyopathy
  21. Hemodynamic Progression and Outcome of Asymptomatic Aortic Stenosis in Primary Care
  22. Recommendations on Reintroduction of Agalsidase Beta for Patients with Fabry Disease in Europe, Following a Period of Shortage
  23. Ventricular and Supraventricular Tachyarrhythmias Associated with Hypertrophic Cardiomyopathy
  24. Microvascular Function Is Selectively Impaired in Patients With Hypertrophic Cardiomyopathy and Sarcomere Myofilament Gene Mutations
  25. Cardiovascular Events in Patients With Fabry Disease
  26. Timing and Significance of Exercise-Induced Left Ventricular Outflow Tract Pressure Gradients in Hypertrophic Cardiomyopathy
  27. Prevalence and clinical significance of acquired left coronary artery fistulas after surgical myectomy in patients with hypertrophic cardiomyopathy
  28. Clinical Features and Outcome of Hypertrophic Cardiomyopathy Associated With Triple Sarcomere Protein Gene Mutations
  29. DETERMINANTS OF LEFT ATRIAL VOLUME IN HEALTHY INDIVIDUALS AND ATHLETES
  30. CARDIOVASCULAR EVENTS IN PATIENTS WITH FABRY DISEASE: NATURAL HISTORY DATA FROM THE FABRY REGISTRY
  31. Distal limb pain as presenting feature of fabry disease
  32. Echocardiography in patients with hypertrophic cardiomyopathy: usefulness of old and new techniques in the diagnosis and pathophysiological assessment
  33. Hypertrophic Cardiomyopathy at 50
  34. The Left Ventricular Outflow in Hypertrophic Cardiomyopathy: From Structure to Function
  35. Microvascular Dysfunction, Myocardial Ischemia, and Progression to Heart Failure in Patients with Hypertrophic Cardiomyopathy
  36. Diagnostic accuracy of extended-length electrocardiogram in differentiating between athlete's heart and hypertrophic cardiomyopathy
  37. The Many Faces of Hypertrophic Cardiomyopathy: From Developmental Biology to Clinical Practice
  38. Looking for Hypertrophic Cardiomyopathy in the Community: Why Is It Important?
  39. The Case for Myocardial Ischemia in Hypertrophic Cardiomyopathy
  40. Developmental origins of hypertrophic cardiomyopathy phenotypes: a unifying hypothesis
  41. Relationship between atrial fibrillation and blunted hyperemic myocardial blood flow in patients with hypertrophic cardiomyopathy
  42. Reply
  43. Tunneled left anterior descending artery in a child with hypertrophic cardiomyopathy
  44. Assessment and Significance of Left Ventricular Mass by Cardiovascular Magnetic Resonance in Hypertrophic Cardiomyopathy
  45. The familial hypertrophic cardiomyopathy-associated myosin mutation R403Q accelerates tension generation and relaxation of human cardiac myofibrils
  46. Myofilament Protein Gene Mutation Screening and Outcome of Patients With Hypertrophic Cardiomyopathy
  47. Reply
  48. Surgical Myectomy Versus Alcohol Septal Ablation for Obstructive Hypertrophic Cardiomyopathy
  49. Usefulness and Safety of Transcatheter Ablation of Atrial Fibrillation in Patients With Hypertrophic Cardiomyopathy
  50. 'End-stage' hypertrophic cardiomyopathy: from mystery to model
  51. Does LV outflow tract obstruction increase the risk of sudden death in hypertrophic cardiomyopathy?
  52. Hypertrophic Cardiomyopathy in Anderson-Fabry Disease
  53. Midventricular Obstruction and Clinical Decision-Making in Obstructive Hypertrophic Cardiomyopathy
  54. Prognostic Significance of Left Atrial Size in Patients With Hypertrophic Cardiomyopathy (from the Italian Registry for Hypertrophic Cardiomyopathy)
  55. A molecular screening strategy based on β-myosin heavy chain, cardiac myosin binding protein C and troponin T genes in Italian patients with hypertrophic cardiomyopathy
  56. Relevance of Coronary Microvascular Flow Impairment to Long-Term Remodeling and Systolic Dysfunction in Hypertrophic Cardiomyopathy
  57. The Italian registry for hypertrophic cardiomyopathy: A nationwide survey
  58. Gender-Related Differences in the Clinical Presentation and Outcome of Hypertrophic Cardiomyopathy
  59. Long-Term Effects of Surgical Septal Myectomy on Survival in Patients With Obstructive Hypertrophic Cardiomyopathy
  60. Hypertrophic cardiomyopathy in the community: why we should care
  61. 1032-124 Coronary microvascular dysfunction and long-term left ventricular remodeling in hypertrophic cardiomyopathy
  62. 1032-119 Prevalence of mutations in the cardiac myosin-binding protein C gene among tuscan patients with hypertrophic cardiomyopathy
  63. 839-1 The long-term effect of surgical myectomy on survival in patients with obstructive hypertrophic cardiomyopathy
  64. Prevalence and clinical profile of troponin T mutations among patients with hypertrophic cardiomyopathy in tuscany
  65. Coronary Microvascular Dysfunction and Prognosis in Hypertrophic Cardiomyopathy
  66. Evidence that left ventricular outflow tract obstruction is a predictor of outcome in patients with hypertrophic cadiomyopathy
  67. Effect of Left Ventricular Outflow Tract Obstruction on Clinical Outcome in Hypertrophic Cardiomyopathy
  68. Maximum left ventricular thickness and risk of sudden death in patients with hypertrophic cardiomyopathy
  69. Clinical profile of stroke in 900 patients with hypertrophic cardiomyopathy
  70. Clinical significance of atrial fibrillation in hypertrophic cardiomyopathy
  71. Prognostic value of systemic blood pressure response during exercise in a community-based patient population with hypertrophic cardiomyopathy
  72. Coronary vasodilator reserve is impaired in patients with hypertrophic cardiomyopathy and left ventricular dysfunction
  73. Hypertrophic cardiomyopathy in tuscany: Clinical course and outcome in an unselected regional population
  74. 901-95 Stress-induced Subendocardial Underperfusion: A Potential Mechanism of Ischemia in Hypertrophic Cardiomyopathy (HCM)
  75. 925-43 Hypertrophic Cardiomyopathy in Tuscany: More Benign Clinical Course and Outcome in an Unselected Regional Population
  76. Effect of verapamil on absolute myocardial blood flow in hypertrophic cardiomyopathy
  77. Both aborted sudden cardiac death and end-stage phase in hypertrophic cardiomyopathy
  78. Long-term outcome of patients with hypertrophic cardiomyopathy successfully resuscitated after cardiac arrest
  79. Pathophysiology and Clinical Consequences of Atrial Fibrillation in Hypertrophic Cardiomyopathy
  80. Other Modes of Disability or Death Including Stroke, and Treatment Strategies, in Hypertrophic Cardiomyopathy